NAD+ IV therapy: what the hype gets wrong about the science

What did @nexgenhealthofficial actually say?

The creator laid out a specific NAD+ IV protocol: four infusions within 14 days constitutes a "loading dose," and doing them on consecutive days (day one through four) delivers "optimal results." They're framing this as clinical best practice, something Next Gen Health uses routinely with patients.

That's a pretty confident claim for a treatment that doesn't have a standardized, FDA-approved dosing protocol. The video reads less like an explanation of emerging evidence and more like a sales pitch with clinical-sounding language layered on top. The word "optimal" is doing a lot of heavy lifting here with no data behind it.

Does the science back this up?

Partially, but the word "optimal" is where this falls apart. There is real science behind NAD+ and its role in cellular metabolism, but the specific 4-infusion loading protocol presented here is not validated by peer-reviewed clinical trials.

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme involved in mitochondrial function, DNA repair, and energy metabolism. Research by Rajman, Chwalek, and Sinclair (2018, Cell Metabolism) confirmed that NAD+ levels decline with age and that precursor supplementation can restore them in animal models. Martens et al. (2023, Nature Aging) showed oral NMN supplementation raised blood NAD+ in older adults, but IV-specific protocols remain largely unstudied in rigorous human trials. A loading-dose framework, the kind used for drugs like iron infusions or immunotherapy, requires pharmacokinetic data to justify. That data doesn't publicly exist for NAD+ IV therapy in the way the creator implies.

What did they get wrong (or right)?

They got the general concept of NAD+ depletion right. Aging and metabolic stress do lower intracellular NAD+ levels, and IV delivery does bypass gastrointestinal absorption, which is a legitimate pharmacological advantage over oral routes for some compounds. Give credit where it's due.

But "loading dose" is a term borrowed from established pharmacology, where it means a precisely calculated higher initial dose to rapidly reach therapeutic plasma concentration. The creator uses it without citing any pharmacokinetic rationale. There is no published human trial establishing that four NAD+ IVs in 14 days is a threshold, let alone an optimal one. The claim that back-to-back infusions on days one through four will get you "optimal results" is not supported by comparative trial data. It may be informed by clinical observation, but that's not the same thing, and presenting it as protocol implies a level of evidence that doesn't exist yet.

What should you actually know?

NAD+ IV therapy is genuinely interesting and not pseudoscience, but the clinical protocols being sold right now are running ahead of the evidence. Here's what the research actually supports.

• NAD+ levels decline with age and chronic illness. That part is well-documented (Verdin, 2015, Science).
• IV administration does raise blood NAD+ levels quickly. A small human study by Airhart et al. (2017, PLOS ONE) confirmed NAD+ precursor infusion increases circulating levels.
• There are no published RCTs comparing 4-infusion loading protocols to other schedules. The "optimal" claim is not evidence-based.
• Side effects from rapid NAD+ infusions, including nausea, flushing, and chest tightness, are clinically reported and rate-dependent. Fast infusions carry real risks that weren't mentioned.
• Anyone considering this should consult a licensed clinician who can review their full health picture, not just a TikTok protocol.

The bottom line

The creator isn't spreading outright misinformation about NAD+ biology, but they are presenting a specific dosing framework, "four IVs within 14 days" for "optimal results," as though it's a clinical standard. It isn't. It may reflect what some clinics have converged on through practice, but practice patterns are not clinical evidence. Patients deserve to know the difference before they pay several hundred dollars per infusion.